Search

Author/Creator Arkenau, H.-T.

1. An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. (November 2018)

Authors:
Arkenau, H.-T.; Italiano, A.; Mak, G.; Toulmonde, M.; Baird, R.D.; Garcia-Corbacho, J.; Plummer, R.; Flynn, M.; Forster, M.; Wilson, R.H.; Tosi, D.; Adenis, A.; Donaldson, K.; Posner, J.; Kawabata, I.; Arimura, A.; Deva, S.; Spicer, J.
Journal:
European journal of cancer
Issue:
Volume 103(2018)
Page Start:
17
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL. (23rd June 2022)

Authors:
Sharp, A.; Williams, A.; Blagden, S.; Plummer, R.; Hochhauser, D.; Krebs, M. G.; Pacey, S.; Evans, J.; Whelan, S.; Nandakumar, S.; Rogers, S.; Jameson, K. L.; Basile, F. G.; de Bono, J.; Arkenau, H.-T.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1970
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search